Pages that link to "Q26829865"
Jump to navigation
Jump to search
The following pages link to A Blueprint for HIV Vaccine Discovery (Q26829865):
Displaying 50 items.
- bNAber: database of broadly neutralizing HIV antibodies (Q24567758) (← links)
- Can follicular helper T cells be targeted to improve vaccine efficacy? (Q26753848) (← links)
- Emerging Vaccine Technologies (Q26783764) (← links)
- The role of Fc-FcγR interactions in IgG-mediated microbial neutralization (Q26797466) (← links)
- Structural insights on the role of antibodies in HIV-1 vaccine and therapy (Q26829461) (← links)
- A New Scientific Paradigm may be Needed to Finally Develop an HIV Vaccine (Q26830360) (← links)
- A brief history of the global effort to develop a preventive HIV vaccine (Q26851165) (← links)
- Mechanisms of HIV protein degradation into epitopes: implications for vaccine design (Q26866505) (← links)
- Antibody responses to envelope glycoproteins in HIV-1 infection (Q26991572) (← links)
- Effective T helper cell responses against retroviruses: are all clonotypes equal? (Q26995251) (← links)
- HIV-1 neutralizing antibodies: understanding nature's pathways (Q27000480) (← links)
- Vaccines for the 21st century (Q27007529) (← links)
- Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection (Q27022652) (← links)
- Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies (Q27644515) (← links)
- Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity (Q27654848) (← links)
- Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors (Q27677104) (← links)
- Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120 (Q27678306) (← links)
- Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign (Q27681806) (← links)
- Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers (Q27683553) (← links)
- Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory (Q28071559) (← links)
- Boosting vaccine efficacy the natural (killer) way (Q28084474) (← links)
- Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design (Q28084672) (← links)
- Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers (Q28263063) (← links)
- Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies (Q28263932) (← links)
- Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data (Q28535583) (← links)
- IDEPI: rapid prediction of HIV-1 antibody epitopes and other phenotypic features from sequence data using a flexible machine learning platform (Q28543211) (← links)
- Escherichia coli surface display of single-chain antibody VRC01 against HIV-1 infection (Q30153279) (← links)
- Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem (Q30234773) (← links)
- Systems serology for evaluation of HIV vaccine trials (Q30238729) (← links)
- Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1 (Q30353580) (← links)
- Passive immunization against HIV/AIDS by antibody gene transfer. (Q30358434) (← links)
- Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design (Q30374314) (← links)
- Status of vaccine research and development of vaccines for HIV-1. (Q30385813) (← links)
- Sulfotyrosine dipeptide: Synthesis and evaluation as HIV-entry inhibitor (Q30391222) (← links)
- Recombinant expression, purification, and biophysical characterization of the transmembrane and membrane proximal domains of HIV-1 gp41. (Q30601090) (← links)
- Immunologic and Virologic Mechanisms for Partial Protection from Intravenous Challenge by an Integration-Defective SIV Vaccine (Q32183405) (← links)
- HIV-1 vaccines: challenges and new perspectives (Q33577972) (← links)
- Glycoproteomic analysis identifies human glycoproteins secreted from HIV latently infected T cells and reveals their presence in HIV plasma (Q33589518) (← links)
- Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates (Q33612459) (← links)
- Novel directions in HIV-1 vaccines revealed from clinical trials (Q33645528) (← links)
- Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection (Q33702217) (← links)
- Immunoglobulin VH gene diversity and somatic hypermutation during SIV infection of rhesus macaques. (Q33712279) (← links)
- CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies (Q33743734) (← links)
- Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239 (Q33744109) (← links)
- Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals (Q33808304) (← links)
- Proteome-wide analysis of HIV-specific naive and memory CD4( ) T cells in unexposed blood donors (Q33826872) (← links)
- Synthetic carbohydrate antigens for HIV vaccine design (Q33909079) (← links)
- Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization (Q33946158) (← links)
- HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1 (Q33947008) (← links)
- The promise and challenge of high-throughput sequencing of the antibody repertoire. (Q33962293) (← links)